New study shows critical improvements in treating rare eye cancer in children

The evolution of retinoblastoma treatment over the past 15 years has resulted in a higher likelihood of vision preservation without compromising survival, according to research released at the Society of NeuroInterventional Surgery’s (SNIS) 21st Annual Meeting.

Retinoblastoma, a rare eye cancer that affects young children, carries a risk of impaired vision and removal of one or both eyes. It is fatal if left untreated.

Previously published in the Journal of NeuroInterventional Surgery, the study, “Advancement in Super-Selective Catheterization and Drug Selection for Intra-Arterial Chemotherapy for Retinoblastoma: A 15-year Evolution,” reviewed how children received intra-arterial chemotherapy (IAC), the gold standard for treating retinoblastoma, by delivering chemotherapy directly to the affected eye.

Using IAC helps to minimize the need to remove a patient’s affected eye and maximizes their ability to see after treatment, as well as their potential to survive the cancer.

The research team—composed of neurointerventionalists from New York-Presbyterian Hospital/Weill Cornell Medicine, and ophthalmologic oncologists at Memorial Sloan Kettering Cancer Center—reviewed medical records for 571 patients separated into three cohorts five years apart.

The data was evaluated to determine how routes of vascular access to the ophthalmic artery have evolved over time, how many patients have had complications from the procedure, and what combinations of chemotherapy drugs patients have received.

Researchers found that, of a total of 2,402 attempted IAC sessions, 2,391 (99.5%) were successful. Success rates of super-selective catheterizations, where the ophthalmic artery was catheterized directly, also improved over time; 80% of the earliest procedures were successful compared to 89.2% of the most recent procedures.

Procedure complication rates stayed very low over time, at 0.7% for the earliest cohort, 1.1% in the middle cohort and 0.6% in the most recent cohort. In addition, researchers found that more and more children have successfully received a three-chemotherapy combination from 21% of the earliest cohort to 66.7% of the most recent cohort. Finally, the authors proposed a stepwise algorithm to help others maximize direct vascular access to the ophthalmic artery.

“We are proud to share our history of ongoing success in using this minimally invasive method to care for some of our youngest cancer patients,” said Gary Kocharian, MD, Neurosurgery Chief Resident and Endovascular Neurosurgery Fellow at New York-Presbyterian Hospital.

“Giving children the opportunity to both keep their eyesight and beat this disease is life-changing for families across the world. We look forward to seeing what innovations are made in the next 15 years,” said Y. Pierre Gobin, MD, one of the earliest pioneers of this revolutionary procedure.

Provided by
Society of NeuroInterventional Surgery